Webinar

Thu, Dec 8, 2022
10AM ET

Controlling distribution and handling risks faced by pharmaceutical companies

Register now

11/21/2022 09:34:34

Home | What Rishi Sunak can do for the UK pharma industry
In this issue
Contents
CSafe
Tripletree
Briefing
Industry news
The pharma industry briefing
BEA Technologies
Mimotopes Company Insight
Mimotopes
Comment
GSK speeds up the race to market first RSV vaccine for older adults
Biden’s directive on foreign biotech investments impacts manufacturers
Novo Nordisk targets FDA approval for once-weekly insulin after Phase III data
‘Twindemic’ risks warrant immediate steps in Europe and the US
A game of two halves for Roche’s recently approved wet AMD assets
Dr. Paul Lohmann
Nipro
In Depth
What Rishi Sunak can do for the UK pharma industry
Inside the European mass shift to data-driven health solutions
Chronic drug shortages signal difficult outlook for cardiovascular care
Can gene therapies for haemophilia defend their high price tags?
Trial termination analysis unveils a silver lining for patient recruitment
New dawn for the EU's joint procurement crisis response
Skyepharma
Bio Image Systems Inc.
In Data
The pharma industry found it easier to fill AI vacancies in Q3 2022
Internet of things hiring levels in the pharma dropped in October 2022
Artificial intelligence hiring levels in the pharma dropped in October 2022
Baxter
Events
Next issue